Back to top
more

CRISPR Therapeutics (CRSP)

(Real Time Quote from BATS)

$54.38 USD

54.38
314,130

+0.65 (1.21%)

Updated Apr 26, 2024 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

A Comprehensive Guide to Genomic ETFs

by Zacks Equity Research

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -7.62% and 96.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.

Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.

CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.

Neena Mishra headshot

Should You Buy Beaten-Down Biotech Stocks & ETFs?

by Neena Mishra

We highlight 4 ETFs that have started rebounding after a brutal sell-off

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $76.50 in the latest trading session, marking a +0.9% move from the prior day.

EyePoint Pharmaceuticals (EYPT) Soars 21.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $83.39, marking a +1.81% move from the previous day.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $81.91, marking a +1.5% move from the previous day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $76.70 in the latest trading session, marking a -1.92% move from the prior day.

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

by Zacks Equity Research

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

A Comprehensive Guide to Genomic ETFs

by Zacks Equity Research

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

CRISPR Therapeutics AG (CRSP) Stock Moves -0.09%: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $66.90, marking a -0.09% move from the previous day.

CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

by Zacks Equity Research

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.

    CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $55.68, marking a +0.27% move from the previous day.

    CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.

    M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus

    by Zacks Equity Research

    We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.